TheraRadar
← Back
Data updated: Jun 12, 2026

SYNTHON PHARMS

Generics

SYNTHON PHARMS is a generic drug manufacturer focused on Neurology, Cardiovascular, Metabolic.

2001
Since
9
Drugs
-
Trials
0
New Drugs (2yr)

SYNTHON PHARMS's Key Drugs

SYNTHON PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SYNTHON PHARMS's Recent FDA Approvals

New NDA/BLA approvals for SYNTHON PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SYNTHON PHARMS's Therapeutic Areas

SYNTHON PHARMS's approved drugs and pipeline span 3 therapeutic areas, led by Neurology and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 33%
1 drugs
Cardiovascular 33%
1 drugs
Metabolic 33%
1 drugs

SYNTHON PHARMS's Top Competitors

SYNTHON PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novo Nordisk, AZURITY, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SYNTHON PHARMS Pipeline Snapshot

Active clinical trials for SYNTHON PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling